Galapagos’ investigative drug GLPG0778 has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. GPLG0778 showed dose-dependent, statistically-significant and selective suppression of an induced inflammatory response in volunteers, indicating specific inhibition of the medicine’s target in vivo. The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778. GLPG0778 is part of Galapagos’ immuno-infl...